BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $103.00

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target increased by Bank of America from $99.00 to $103.00 in a research report report published on Thursday,Benzinga reports. Bank of America currently has a buy rating on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on BMRN. Citigroup cut their […]